Seminars in Immunology 24 (2012) 429–435
Contents lists available at SciVerse ScienceDirect
Seminars in Immunology
journal homepage: www.elsevier.com/locate/ysmim
Review
mTOR, linking metabolism and immunity
Xiaojin Xu 1 , Lilin Ye 1 , Koichi Araki, Rafi Ahmed ∗
Emory Vaccine Center and Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322, USA
a r t i c l e
i n f o
Keywords:
mTOR
Rapamycin
T cells
B cells
Metabolism
Autophagy
a b s t r a c t
mTOR is an evolutionarily conserved serine/threonine kinase that plays a critical role in cell growth
and metabolism by sensing different environmental cues. There is a growing appreciation of mTOR in
immunology for its role in integrating diverse signals from the immune microenvironment and coordinating the functions of immune cells and their metabolism. In CD8 T cells, mTOR has shown to influence
cellular commitment to effector versus memory programming; in CD4 T cells, mTOR integrates environmental cues that instruct effector cell differentiation. In this review, we summarize and discuss recent
advances in the field, with a focus on the mechanisms through which mTOR regulates cellular and humoral
immunity. Further understanding will enable the manipulation of mTOR signaling to direct the biological
functions of immune cells, which holds great potential for improving immune therapies and vaccination
against infections and cancer.
© 2013 Elsevier Ltd. All rights reserved.
1. Introduction
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that controls cell proliferation and
metabolism in response to a diverse range of extracellular
stimuli such as the availability of nutrients, growth factors and
stress [1,2]. Deregulation of the mTOR signaling pathway has
shown to be closely associated with cancers, metabolic diseases as
well as aging [1]. A growing body of evidence suggests that mTOR
regulates functional outcome in a wide range of immune cells,
including T cells, B cells, dendritic cells, macrophages, neutrophils,
mast cells and natural killer cells [3]. Here we review the recent
progress regarding the role of mTOR in the regulation of T cell and
B cell responses and discuss the potential mechanism of mTOR
as a metabolic checkpoint in influencing an immune response.
We highlight the potential for improving vaccine efficacy and
anti-tumor therapy by pharmacological targeting of the mTOR
pathway.
2. mTOR signaling cascades
mTOR is physiologically active in complex with accessory proteins that determine the functional outcomes of mTOR signaling.
The two currently recognized multi-molecular signaling forms
of mTOR, mTOR complex 1(mTORC1) and mTOR complex 2
∗ Corresponding author at: G211 Rollins Research Bldg., Emory University, 1510
Clifton Rd., Atlanta, GA 30322, USA. Tel.: +1 404 727 3571; fax: +1 404 727 3722.
E-mail address: rahmed@emory.edu (R. Ahmed).
1
These authors contributed equally to this work.
1044-5323/$ – see front matter © 2013 Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.smim.2012.12.005
(mTORC2), are differentially activated by distinct extracellular and
intracellular signals [4], as illustrated in Fig. 1. mTORC1 comprises mTOR and four subunits, including the scaffolding protein,
regulatory-associated protein of mTOR (RAPTOR), DEP-containing
mTOR-interacting protein (DEPTOR), mammalian lethal with Sec13
protein 8 (mLST8) and the Proline-Rich Akt Substrate 40 kDa
(PRAS40). mTORC2 comprises mTOR and five subunits, including the scaffold protein Raptor-Independent Companion of TOR
(RICTOR), mammalian stress-activated protein kinase interacting
protein 1 (mSIN1), DEPTOR, mLST8 and the Protein Observed with
RICTOR (PROTOR) [4].
mTORC1-signaling events are associated with cellular growth
and proliferation in response to a variety of environmental cues,
such as growth factors and nutrient availability, as well as immuneregulatory signals [1]. Classically, growth factors, cytokines or other
co-stimulatory signals activate PI3 kinase (PI3K), leading to activation of the protein kinase Akt. Akt in turn activates mTOR through
inhibition of the mTORC1 repression factor Tuberous Sclerosis
Complex (TSC). TSC is a hetero-dimeric complex, comprising the
TSC1 and TSC2 subunits, which functions as a GTPase-activating
protein by inhibition of the GTP-binding protein Rheb. Rheb is an
essential component of mTORC1 activation. Upon de-activation of
TSC, the active, GTP-bound Rheb interacts with mTORC1 to promote signaling. Akt can further phosphorylate PRAS40, relieving it
from inhibiting mTORC1. Reciprocal to the activating signals from
Akt, a decrease in the ATP/ADP ratio can activate AMP-activated
Protein Kinase (AMPK) which in turn inhibits mTOR activity by
phosphorylation of TSC2 and/or RAPTOR [1].
The mTORC1 signaling pathway controls the expression of a
diverse range of genes that promote cellular growth and proliferation. The most well-characterized of these pathways is the
430
X. Xu et al. / Seminars in Immunology 24 (2012) 429–435
Fig. 1. mTOR signaling cascade. The mTOR kinase forms two functionally distinct complexes: mTORC1 and mTORC2. mTOR senses environmental cues, including growth
factors, nutrients and immune signals, through mTORC1 and mTORC2. mTORC1 controls cellular activities, such as autophagy, protein translation as well as cell growth and
metabolism, while mTORC2 regulates cytoskeleton organization, cell survival as well as metabolism. Rapamycin forms complex with FKBP12 and inhibits the kinase activity
of mTORC1. Inhibition of mTORC2 requires high doses or prolonged exposure. Arrows indicate activation signal whereas bars correlates to inhibition.
phosphorylation of p70-S6 kinase (S6K) and eukaryotic initiation
factor 4E binding protein (4E-BP), which promotes protein translation [5,6]. Active mTORC1 also down-regulates the autophagy
pathway and promotes lipid biosynthesis as well as mitochondrial
biogenesis. Enhanced mitochondrial biogenesis was observed upon
increased mTORC1 activity by genetically deleting the mTORC1
repression factor, TSC1 in hematopoietic stem cells [7]. Signaling
events involving mTORC2 are less well-characterized. mTORC2
signaling has been associated with cell survival and cytoskeleton
organization [8,9]. The finding that Akt is also a downstream target of mTORC2 implies both forms of active mTOR function in a
synchronized manner toward the same physiological outcomes [1].
mTORC1 is a specific target of rapamycin. Rapamycin is a small
molecule drug, derived from Streptomyces hygroscopicus, that binds
a 12-kDa FK506 binding protein (FKBP12) to form the rapamycinFKBP12 complex, which is an inhibitor of mTORC1 [10]. In addition
to the blockade of mTORC1 activity, prolonged rapamycin exposure is implicated in inhibiting mTORC2 [11]. Clinically, rapamycin
is used as an immune-suppressive agent for the prevention of allograft rejection. The immunosuppressive effect has been largely
attributed to the inhibition of T cell proliferation [12]. However,
recent observations of immunostimulatory and immunoregulatory
effects of rapamycin have indicated a broader influence of mTOR in
controlling the biological activities of immune cells [13–16].
3. mTOR in the differentiation of effector CD4 T cells and
regulatory T cells
Upon antigen stimulation, naïve CD4 T cells can differentiate
into several distinct subsets, including Th1, Th2, Th17, follicular
helper T cells (Tfh) and regulatory T cells (Treg). Each subset has a
unique transcription factor critical for specific lineage differentiation, i.e., T-bet for Th1, Gata-3 for Th2, ROR␥t for Th17, Bcl-6 for Tfh,
and Foxp3 for Treg, respectively [17]. In addition, differentiation
into these lineages is coordinated by distinct downstream cytokinemediated transcription factors, known as Signal Transducer and
Activator of Transcription (STATs) and associated cytokines, such as
IL-12/STAT4 (Th1), IL-4/STAT6 (Th2) and IL-6/STAT3 (Th17) [18,19].
Recently, accumulated evidence from several studies highlight that
mTOR activity is closely associated with distinct CD4 T helper lineage differentiation [20,21]. It has been shown that mTOR-null CD4
T cells were unable to differentiate into Th1, Th2 and Th17 cells
under appropriate skewing conditions [22]. This was largely due
to impaired phosphorylation of corresponding STATs in response
to different cytokine stimuli, leading to the inability of inducing
the expression of lineage-specific transcriptional factors [14,22]. It
has been further demonstrated that mTORC1 and mTORC2 have
differential role in lineage differentiation of CD4 T cells [23]. Upon
conditional deletion of the specific upstream activator for mTORC1,
Rheb, the CD4 T cells were incapable of developing to either Th1
or Th17, while Th2 cell differentiation from these Rheb-deficient
cells was unperturbed [23]. Conversely, when RICTOR, the essential component of mTORC2, was conditionally deleted, RICTOR-null
CD4 T cells failed to differentiate into Th2 cell type, but Th1 and
Th17 lineage differentiation remained intact [23]. Accordingly, corresponding lineage-specific STATs were inactivated by mTORC1 or
mTORC2 inhibition [23]. Thus these studies suggest that mTORC1
and mTORC2 selectively regulate Th1, Th2 and Th17 differentiation. Paradoxically, in an earlier study, it was shown that both Th1
and Th2 differentiation were abolished when RICTOR was deleted
specifically in CD4 T cells [24]. This discrepancy was regarded as a
possible consequence by using different conditional deletion system of RICTOR gene (Lck-Cre versus CD4-Cre), which leads to the
deletion of RICTOR at different stage of CD4 T cell development [25].
Overall, these data clearly demonstrate that mTOR signaling regulates the differentiation of Th1, Th2 and Th17 subsets. Distinct from
Th1 and Th17 cells, Tfh cells are specialized in providing help to B
cells for optimal antibody production [26]. Despite extensive studies of mTOR in other CD4 T cell lineages, its role in the regulation
of Tfh differentiation remains to be elucidated.
In contrast to effector CD4 lineages, Foxp3+ T regulatory cells
(Tregs) maintain tolerance to self-antigens and suppress effector functions of other T cell subsets [27]. Rapamycin treatment
or genetic ablation of mTOR drives the preferential expansion of
Tregs in vitro and in vivo [22,28]. These data suggest that mTOR
activity antagonizes Treg differentiation. Accumulating evidences
X. Xu et al. / Seminars in Immunology 24 (2012) 429–435
suggest that CD4T cell differentiation is critically coupled to cellular
metabolic state [29–31]. It has been postulated that Treg differentiation depends more on fatty acid oxidation and mitochondrial
respiration as an energy source, whereas effector T cells display
highly glycolytic metabolic demand [30,32]. Consistent with this
point, mTOR promotes glycolysis, but not fatty acid oxidation, by
selectively increasing the translation of glycolysis related proteins
[33,34]. In addition to the regulation of metabolic state, rapamycin
inhibition of mTOR or mTOR deficiency has also been reported to
increase responsiveness to TGF-, leading to elevated Treg expansion [22,35].
4. mTOR in B cell response
In contrast to extensive studies in T cells, the function of mTOR
in B cell responses has received minimal attention. In a T celldependent B cell response, naïve B cells become activated and
migrate from the B cell follicle to the T–B border, whereby these
cells will interact with cognate CD4 T cells [36]. Subsequently, T
cell-helped B cells will either differentiate into short-lived extrafollicular plasma cells or migrate into B cell follicles to initiate a
germinal center (GC) reaction [37]. Germinal centers are unique
tertiary compartments within B-cell follicles, supporting rapid
proliferation and somatic hypermutation/affinity maturation of
activated B cells [38]. The consequence of a GC reaction is to
establish a high-affinity, long-lived memory pool that contains
memory B cells in lymphoid tissues and plasma cells in bone marrow [39]. Therefore, B cell responses involve a series of cellular
events, including migration, growth/proliferation and differentiation. As mentioned, mTOR regulates almost all of these events
in many other cell types, including CD4 T cells. However, little is
known regarding how mTOR coordinates these events in B cell
responses (Fig. 2). Since mTOR integrates various signals to dictate the fate of CD4 T cell differentiation, it is of great interest to
investigate whether mTOR signaling also determines the differentiation outcomes of activated B cells at the T–B border or within the
germinal center. Furthermore, it is important to dissect whether
mTOR mediated metabolism is linked to B cell differentiation and
function.
To date, there are very limited publications regarding mTOR
regulation of B cell immunity. Several earlier studies have demonstrated that the inhibition of mTOR with rapamycin blunted B
cell proliferation and plasma cell differentiation [40–44]. However,
most of these experiments were performed in vitro using strong
BCR or TLR agonists, which may not recapitulate the complexity
of B cell responses under physiological conditions. Recently, two
mouse models with altered mTOR activity by genetic targeting have
been used to study role of mTOR in B cell function [45,46]. In the
mTOR hypomorphic mouse, B cells with reduced mTOR activity
showed decreased differentiation into plasma cells in response to
antigen stimulation [45]. In contrast, conditional deletion of mTOR
inhibitory TSC-1 molecule in B cells leads to constitutively hyperactive mTOR signaling, and also results in defects in plasma cell
differentiation after immunization [46]. The observed discrepancy
of these studies could be explained by few possibilities: first, in
both studies the development of naive B cells was compromised
prior to the antigen stimulation due to changes introduced in their
mTOR activity [45,46]; secondly, optimal antibody responses may
require a defined range of mTOR activity, i.e., either too high or
too low mTOR activity could be suboptimal for plasma cell differentiation. Future studies should employ systems where the mTOR
signaling pathway could be specifically targeted at different stages
of B cell response, including B cell activation, GC reaction, and memory B cell/plasma cell differentiation. Since antibody responses are
the correlate of protective immunity for many successful human
431
vaccines [47], a better understanding of the role of mTOR in B cell
responses will facilitate the rational design of future vaccines.
5. mTOR in CD8 T cell memory development
Recent work provided insight into how mTOR could control
the outcome of memory CD8 T cell differentiation [48–50], however the mechanism by which mTOR-signaling pathways sense and
induce metabolic changes to influence the fate of immune effector
cells has yet to be determined. Upon recognizing cognate antigen,
CD8 T cells undergo robust proliferation followed by rapid contraction, whereby most effector cells undergo apoptosis, leaving
only a small proportion to become long-term protective memory
cells [51,52]. In the lymphocytic choriomeningitis virus (LCMV)
acute infection model, the administration of rapamycin during the
expansion phase following viral infection markedly enhanced the
number of virus-specific memory CD8 T cells. These findings were
attributed to an increased number of effector cells committed to
become memory precursors. Furthermore, rapamycin treatment
during the contraction phase accelerated conversion of effector CD8
T cells in becoming long-lived memory cells, characterized by the
re-expression of CD62L, CD127 on the cell surface and an increased
level of the anti-apoptotic molecule, Bcl-2 [16,49]. These memory cells exhibited both superior recall ability as well as enhanced
protective capability, and the effect of rapamycin was identified
as being intrinsic to the CD8 T cells, acting through the downregulation of mTOR activity [49]. Likewise, LCMV-specific CD8 T
cells, expanded in the presence of rapamycin in vitro, generated
more memory CD8 T cells after adoptive transfer into mice [53].
These CD8 T cells treated with rapamycin had an elevated level
of oxidative phosphorylation, resulting in enhanced cell survival
upon the withdrawal of growth factors. In contrast, increased activity of mTORC1 in CD8 T cells by the addition of IL-12 resulted
in a reduced number of memory CD8 T cells [50]. Equivalent
results were observed by down-regulating a negative regulator of
the PI3K/Akt pathway, PTEN, using a microRNA cluster, miR17-92
[54].
The importance of fatty acid metabolism in memory CD8 T
cells was demonstrated using T cell-specific knockout of a Tumor
Necrosis Factor (TNF) receptor-associated factor (TRAF6). The
TRAF6-deficient cells mounted a robust immune response, but
failed to survive as memory cells [48]. Similar to naïve T cells, memory cells are quiescent and catabolic, employing fatty acid oxidation
and autophagy to meet cellular metabolic demands. AMPK, which
regulates fatty acid metabolism, exhibited reduced activity in the
TRAF6-deficient effector CD8 T cells upon the withdrawal of growth
factors. A drug that activates AMPK, Metformin, was able to restore
the memory population in the TRAF6-deficient CD8 T cells. Furthermore, administration of the mTOR inhibitor, rapamycin, further
improved memory cell development [48]. Rapamycin has shown to
improve lipid metabolism in cells and this may facilitate memory
formation.
Together, these data improve our understanding of the
metabolic requirements and regulation of memory CD8 T cells. To
understand the mechanism by which mTOR inhibition contributes
to improve CD8 T cell memory would involve a careful examination
of all downstream functions. Rapamycin and its derivatives have
been shown to improve CD8 T cell memory in non-human primates
upon vaccinia vaccination and have enabled better protection in
mouse tumor models [48–50,55–57]. Oncogenic activation of
mTOR supports tumor cells in their fast growth, proliferation
and survival. Hence, targeting of the mTOR pathway using small
molecule inhibitors as an anti-tumor therapy has attracted intense
interest. Further investigation of the effects of mTOR inhibition
on the immune response will assist the development of novel
432
X. Xu et al. / Seminars in Immunology 24 (2012) 429–435
Fig. 2. mTOR and B cell responses. In a T-dependent B cell response, naive B cells become activated and differentiate into either short-lived plasma cells (SLPCs) or germinal
center (GC) B cells. With help from antigen-specific cognate Tfh cells, GC B cells undergo rapid proliferation and extensive somatic hypermutation, leading to the eventual
differentiation of long-lived plasma cells (LLPCs) and memory B cells (MBCs). mTOR may have potential roles in integrating various immune and environmental signals in
dictating different outcomes at various stages of B cell differentiation as highlighted in the boxed area.
therapeutic strategies that combine the benefits of inhibiting
tumor growth and enhancing anti-tumor immunity.
6. mTOR in T cell metabolism and functions
In eukaryotic cells, mTOR functions to sense the nutrient availability and to translate this information into an appropriate cellular
response. When energy and nutrients are ample, mTOR is active,
thereby signaling downstream pathways in promoting translation
and biosynthesis and suppressing autophagy for the recycling of
nutrients [4]. Conversely, low mTOR activity indicates an insufficient energy supply, which attenuates biosynthesis and increases
autophagy. In the context of the immune response, mTOR also integrates immunological stimuli and metabolic signals to influence
downstream biological processes. Previous studies have shown
that co-stimulatory molecules such as CD28 could activate mTORC1
activity via the PI3K/Akt pathway [58]. Cykotines such as IL-2 and
IL-4 could also activate mTOR via the same upstream signaling
pathway [59,60]. Conversely, inhibitory signals reduce mTORC1
activity as seen in PD-L1 engagement of PD-1 on regulatory T cells
[61].
Naïve T cells and activated T cells have drastically different
metabolic signatures [62]. mTOR signaling in both cell types illustrates this dichotomy by variously facilitating increased nutrient
uptake and energy production. Naïve T cells employ catabolic
metabolism, which utilizes lipid oxidation and autophagy to
provide energy and substrates for basal levels of biosynthesis
(Fig. 3). Upon receiving activation signals via TCR and costimulatory receptors, naïve T cells must ready themselves to undergo a
metabolic reprogram in preparation of the surge in bioenergetic
demands required for a vigorous clonal expansion [63–65]. Activated T cells switch from catabolic to anabolic in their metabolism,
utilizing aerobic glycolysis and glutaminolysis as a major supply of
ATP as well as metabolic intermediates for fueling the fast synthesis of proteins, lipids, nucleotides and other biosynthetic products.
mTORC1 has been shown to be involved in the up-regulation of
enzymes involved in glycolysis, glutaminolysis and lipid synthesis, as well as in the pentose phosphate pathway to increase cell
surface expression of the glucose transporter, GLUT-1, and the
glutamine transporter, SNAT-2 [34,63,66]. This global metabolic
reprogramming is achieved through controlling transcription factors such as hypoxia-inducible factor (HIF-1␣), sterol-regulatory
element binding protein (SREBP) and c-Myc [34,63]. mTORC1 also
directly up-regulates protein production by phosphorylation of the
translational factor 4E-BP and the S6 kinase, as well as in promoting
amino acid uptake [5,67]. These findings emphasize the critical role
Fig. 3. Metabolic changes of antigen-specific CD8 T cells at various stages of
response to an acute infection. Along with co-stimulatory signals, TCR signaling in
engaging a cognate antigen presented by MHC-I can activate naive CD8 T cells. Naïve
and memory T cells are quiescent, using mainly fatty acid oxidation and autophagy
for basal levels of energy and biosynthesis. Activated T cells and effector T cells have
distinct metabolic signatures. In order to meet the bioenergetic demand of subsequent clonal expansion, naïve T cells undergo metabolic reprogramming, switching
from mitochondrial oxidation to glycolysis, glutominolysis and pentose phosphate
pathway. During contraction phase, where effector T cells transition to become longlived memory T cells, the metabolic program reverts from effector-like (anabolic) to
memory-like (catabolic). This metabolic switch is less well characterized. It is yet to
be determined if this process is immediate or gradual, and whether processes such
as autophagy contribute to this transition. Green represents catabolic metabolism
while red represents anabolic metabolism. The gray pyramid represents the level of
antigen.
X. Xu et al. / Seminars in Immunology 24 (2012) 429–435
for mTORC1 in the generation of effector T cells. This notion would
appear to contradict the observed enhancement in the memory
precursor population at the expansion phase of CD8 T cell response
upon rapamycin treatment [49], however these physiological features are directly associated with the extent of mTOR inhibition
and are rapamycin dose-dependent. Large quantities of rapamycin
inhibited, rather than promoted, CD8 T cell expansion in the LCMV
model [49].
Following antigen clearance, the transition phase of effector to
memory T cell differentiation presents another major metabolic
challenge, involving the reversal from anabolic to catabolic state.
The molecular events underlying this metabolic switch are not well
characterized. Memory T cells are quiescent in nature, using lipid
oxidation and autophagy for energy production. mTOR signaling
promotes the glycolytic metabolic program. Inhibition of this pathway by exposure to rapamycin resulted in a metabolic bias toward
oxidative phosphorylation and produced a larger memory pool
[48,49]. All these data strongly suggest an effective switch in
metabolism toward lipid oxidation during the contraction phase
is likely to produce a better memory pool.
The metabolic processes and mTOR signaling activities of T cells
vary according to environmental stimuli and activation state. Likewise, the influence of rapamycin upon mTOR varies accordingly.
Indeed, more memory CD8 precursor cells were formed upon exposure to rapamycin during the expansion phase, suggesting mTOR
influences cellular commitment immediately following activation
[49]. However, rapamycin had no influence upon the commitment
to T-cell fate when administered during the contraction phase, but
accelerated the conversion of memory precursor cells to the central
memory phenotype. In light of these findings, differences in mTORmediated signaling activities may be a critical component in the
differentiation of subsets of effector CD8 T cells, i.e., into a majority
that are committed to apoptosis and a distinct population of cells
that persist to become the memory population. The precise mechanism of how changes in metabolic status could quantitatively and
qualitatively improve the memory T cell pool and dictate T cell fate
still warrants further investigation.
433
selective, in which Malt1, a direct binding partner of Blc10, was
not degraded. These findings draw a parallel with degradation via
the ubiquitin–proteasome machinery.
The initial growth of activated T cells is characterized by an
increase in cellular size in preparation for the subsequent proliferative burst. During the proliferation stage, autophagy could
be less critical, whereby cells use glycolysis as an alternative and
more efficient source to fuel the biosynthesis required for fast proliferation. Autophagy is possibly inhibited by high-mTOR activity
during the expansion phase, where signaling through the TCR is still
active. Upon transition to the memory phase, mTOR activity returns
to a basal level, and T cells again revert to catabolic metabolic
machinery, where autophagy will again be required for housekeeping functions among memory cells. It is tempting to speculate on
the significance of autophagy in memory cells which are quiescent,
similar to naïve cells, wherein autophagy is important for catabolic
metabolism. One important question is whether autophagy also
involved in mediating the contraction phase, whereby effector T
cells transition to become memory cells. Whether this conserved
nutrient-recycling pathway is required for cellular survival and
function in the absence of activating and co-stimulatory signals has
yet to be determined.
8. Conclusion
Numerous lines of evidence suggest mTOR plays a central role
in regulating the biological outcomes of immune cell stimuli.
However, much remains unknown with regard to the level,
type and specific downstream targets of mTOR signaling in the
immune responses. A key question concerns how mTOR-mediated
metabolism is coupled to immune functions. Furthermore, it is critical to determine whether synergistic or individual downstream
pathways of mTOR activity are required in shaping a given immune
response. Collectively, a greater appreciation of how mTOR pathways influence various immune responses will lead to more precise
and specific manipulation of mTOR signaling, thus facilitating the
development of novel strategies for vaccine development and cancer therapy.
7. Autophagy in T cell differentiation
Acknowledgements
The mechanisms through which downstream effectors of mTOR
influence T cell function and differentiation warrant further investigation. One such physiological function of significant interest is the
autophagy pathway. AMPK and mTORC1 have shown to reciprocally control the activity of this pathway through regulation of the
mammalian autophagy-initiation kinase, Ulk1 [68]. Active mTORC1
directly down-regulates autophagy activity, whereas AMPK promotes it. Autophagy is critical to maintain metabolic homestasis
in quiescent T cells, not only as a nutrient recycle pathway but also
for the removal of protein aggregates, damaged organelles and
invading pathogens [69–72]. The deletion of autophagy-related
genes, such as atg5 and atg7, has resulted in compromised T cell
development and reduced survival/proliferation upon activation
[69,72]. A potential role for autophagy in T cell activation was
based on the finding that autophagosomes accumulated upon T
cell activation in vitro [72,73]. Although these findings initially
appeared contradictory, given that enhanced mTOR activity upon
TCR stimulation would likely result in an anabolic metabolism
and inhibition of autophagy activity, upstream AMPK was shown
to be active in activated T cells, which could promote autophagy
activity [74]. Furthermore, a recent study clearly demonstrated a
role of autophagy during TCR activation, whereby autophagy was
shown to moderate TCR downstream signaling by degrading Bcl10,
an adaptor in TCR-induced activation of NF-B signaling cascade
[75]. Degradation of Bcl10 via the autophagy pathway was highly
This work was supported by grants from the National Institute
of Health (Grant AI30048 and AI088575) and Mérieux foundation
to RA.
References
[1] Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell
2012;149:274–93.
[2] Dazert E, Hall MN. mTOR signaling in disease. Current Opinion in Cell Biology
2011;23:744–55.
[3] Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of
mTOR inhibition. Nature Reviews Immunology 2009;9:324–37.
[4] Laplante M, Sabatini DM. mTOR signaling at a glance. Journal of Cell Science
2009;122:3589–94.
[5] Mamane Y, Petroulakis E, LeBacquer O. Sonenberg N. mTOR, translation initiation and cancer. Oncogene 2006;25:6416–22.
[6] Beugnet A, Tee AR, Taylor PM, Proud CG. Regulation of targets of mTOR (mammalian target of rapamycin) signalling by intracellular amino acid availability.
Biochemical Journal 2003;372:555–66.
[7] Chen C, Liu Y, Liu R, Ikenoue T, Guan KL, Zheng P. TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial
biogenesis and reactive oxygen species. Journal of Experimental Medicine
2008;205:2397–408.
[8] Cybulski N, Hall MN. TOR complex 2: a signaling pathway of its own. Trends in
Biochemical Sciences 2009;34:620–7.
[9] Zinzalla V, Stracka D, Oppliger W, Hall MN. Activation of mTORC2 by association
with the ribosome. Cell 2011;144:757–68.
[10] Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annual
Review of Immunology 1996;14:483–510.
434
X. Xu et al. / Seminars in Immunology 24 (2012) 429–435
[11] Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al. Prolonged
rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Molecular Cell
2006;22:159–68.
[12] Halloran PF. Immunosuppressive drugs for kidney transplantation. New
England Journal of Medicine 2004;351:2715–29.
[13] Salmond RJ, Zamoyska R. The influence of mTOR on T helper cell differentiation and dendritic cell function. European Journal of Immunology
2011;41:2137–41.
[14] Powell JD, Delgoffe GM. The mammalian target of rapamycin: linking T cell
differentiation, function, and metabolism. Immunity 2010;33:301–11.
[15] Araki K, Ellebedy AH, Ahmed R. TOR in the immune system. Current Opinion in
Cell Biology 2011;23:707–15.
[16] Araki K, Youngblood B, Ahmed R. The role of mTOR in memory CD8 T-cell
differentiation. Immunological Reviews 2010;235:234–43.
[17] Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (*).
Annual Review of Immunology 2010;28:445–89.
[18] O’Shea JJ, Lahesmaa R, Vahedi G, Laurence A, Kanno Y. Genomic views of STAT
function in CD4+ T helper cell differentiation. Nature Reviews Immunology
2011;11:239–50.
[19] O’Shea JJ, Paul WE. Mechanisms underlying lineage commitment and plasticity
of helper CD4+ T cells. Science 2010;327:1098–102.
[20] Chi H. Regulation and function of mTOR signalling in T cell fate decisions. Nature
Reviews Immunology 2012;12:325–38.
[21] Waickman AT, Powell JD. Mammalian target of rapamycin integrates diverse
inputs to guide the outcome of antigen recognition in T cells. Journal of
Immunology 2012;188:4721–9.
[22] Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthews KL, Xiao B, et al. The mTOR
kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009;30:832–44.
[23] Delgoffe GM, Pollizzi KN, Waickman AT, Heikamp E, Meyers DJ, Horton MR,
et al. The kinase mTOR regulates the differentiation of helper T cells through the
selective activation of signaling by mTORC1 and mTORC2. Nature Immunology
2011;12:295–303.
[24] Lee K, Gudapati P, Dragovic S, Spencer C, Joyce S, Killeen N, et al. Mammalian
target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2
cell subsets via distinct signaling pathways. Immunity 2010;32:743–53.
[25] Powell JD, Pollizzi KN, Heikamp EB, Horton MR. Regulation of immune
responses by mTOR. Annual Review of Immunology 2012;30:39–68.
[26] Crotty S. Follicular helper CD4 T cells (TFH). Annual Review of Immunology
2011;29:621–63.
[27] Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annual Review of Immunology 2012;30:531–64.
[28] Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+
CD25+ FoxP3+ regulatory T cells. Blood 2005;105:4743–8.
[29] Shi LZ, Wang R, Huang G, Vogel P, Neale G, Green DR, et al. HIF1alpha-dependent
glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. Journal of Experimental Medicine 2011;208:
1367–76.
[30] Michalek RD, Gerriets VA, Jacobs SR, Macintyre AN, MacIver NJ, Mason EF, et al.
Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are
essential for effector and regulatory CD4+ T cell subsets. Journal of Immunology
2011;186:3299–303.
[31] Sundrud MS, Koralov SB, Feuerer M, Calado DP, Kozhaya AE, Rhule-Smith A,
et al. Halofuginone inhibits TH17 cell differentiation by activating the amino
acid starvation response. Science 2009;324:1334–8.
[32] Waickman AT, Powell JD. mTOR, metabolism, and the regulation of T-cell differentiation and function. Immunological Reviews 2012;249:43–58.
[33] Sun Q, Chen X, Ma J, Peng H, Wang F, Zha X, et al. Mammalian target of
rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for
aerobic glycolysis and tumor growth. Proceedings of the National Academy of
Sciences of the United States of America 2011;108:4129–34.
[34] Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1.
Molecular Cell 2010;39:171–83.
[35] Gabrysova L, Christensen JR, Wu X, Kissenpfennig A, Malissen B, O’Garra
A. Integrated T-cell receptor and costimulatory signals determine TGF-betadependent differentiation and maintenance of Foxp3+ regulatory T cells.
European Journal of Immunology 2011;41:1242–8.
[36] Pereira JP, Kelly LM, Cyster JG. Finding the right niche: B-cell migration in the
early phases of T-dependent antibody responses. International Immunology
2010;22:413–9.
[37] Victora GD, Nussenzweig MC. Germinal centers. Annual Review of Immunology
2012;30:429–57.
[38] MacLennan IC. Germinal centers. Annual Review of Immunology
1994;12:117–39.
[39] Gourley TS, Wherry EJ, Masopust D, Ahmed R. Generation and maintenance of
immunological memory. Seminars in Immunology 2004;16:323–33.
[40] Donahue AC, Fruman DA. Distinct signaling mechanisms activate the target of rapamycin in response to different B-cell stimuli. European Journal of
Immunology 2007;37:2923–36.
[41] Sakata A, Kuwahara K, Ohmura T, Inui S, Sakaguchi N. Involvement of a
rapamycin-sensitive pathway in CD40-mediated activation of murine B cells
in vitro. Immunology Letters 1999;68:301–9.
[42] Aagaard-Tillery KM, Jelinek DF. Inhibition of human B lymphocyte cell
cycle progression and differentiation by rapamycin. Cellular Immunology
1994;156:493–507.
[43] Kay JE, Kromwel L, Doe SE, Denyer M. Inhibition of T and B lymphocyte proliferation by rapamycin. Immunology 1991;72:544–9.
[44] Wicker LS, Boltz Jr RC, Matt V, Nichols EA, Peterson LB, Sigal NH. Suppression
of B cell activation by cyclosporin A, FK506 and rapamycin. European Journal
of Immunology 1990;20:2277–83.
[45] Zhang S, Readinger JA, DuBois W, Janka-Junttila M, Robinson R, Pruitt M, et al.
Constitutive reductions in mTOR alter cell size, immune cell development, and
antibody production. Blood 2011;117:1228–38.
[46] Benhamron S, Tirosh B. Direct activation of mTOR in B lymphocytes confers
impairment in B-cell maturation andloss of marginal zone B cells. European
Journal of Immunology 2011;41:2390–6.
[47] Plotkin SA. Vaccines: Correlates of Vaccine-induced Immunity. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of
America, vol. 47; 2008. pp. 401–409.
[48] Pearce EL, Walsh MC, Cejas PJ, Harms GM, Shen H, Wang LS, et al. Enhancing CD8
T-cell memory by modulating fatty acid metabolism. Nature 2009;460:103–7.
[49] Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, et al.
mTOR regulates memory CD8 T-cell differentiation. Nature 2009;460:108–12.
[50] Rao RR, Li Q, Odunsi K, Shrikant PA. The mTOR kinase determines effector versus
memory CD8+ T cell fate by regulating the expression of transcription factors
T-bet and Eomesodermin. Immunity 2010;32:67–78.
[51] Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection.
Journal of Virology 2004;78:5535–45.
[52] Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Surh CD, Ahmed R. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to
long-lived memory cells. Nature Immunology 2003;4:1191–8.
[53] He S, Kato K, Jiang J, Wahl DR, Mineishi S, Fisher EM, et al. Characterization of
the metabolic phenotype of rapamycin-treated CD8+ T cells with augmented
ability to generate long-lasting memory cells. PLoS One 2011;6:e20107.
[54] Wu T, Wieland A, Araki K, Davis CW, Ye L, Hale JS, et al. Temporal expression
of microRNA cluster miR-17-92 regulates effector and memory CD8+ T-cell
differentiation. Proceedings of the National Academy of Sciences of the United
States of America 2012;109:9965–70.
[55] Wang Y, Wang XY, Subjeck JR, Shrikant PA, Kim HL. Temsirolimus an mTOR
inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines.
British Journal of Cancer 2011;104:643–52.
[56] Ferrer IR, Wagener ME, Robertson JM, Turner AP, Araki K, Ahmed R, et al. Cutting
edge: rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell
responses. Journal of Immunology 2010;185:2004–8.
[57] Turner AP, Shaffer VO, Araki K, Martens C, Turner PL, Gangappa S, et al. Sirolimus
enhances the magnitude and quality of viral-specific CD8+ T-cell responses to
vaccinia virus vaccination in rhesus macaques. American Journal of Transplantation 2011;11:613–8.
[58] Colombetti S, Basso V, Mueller DL, Mondino A. Prolonged TCR/CD28 engagement drives IL-2-independent T cell clonal expansion through signaling
mediated by the mammalian target of rapamycin. Journal of Immunology
2006;176:2730–8.
[59] Kuo CJ, Chung J, Fiorentino DF, Flanagan WM, Blenis J, Crabtree GR.
Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature
1992;358:70–3.
[60] Stephenson LM, Park DS, Mora AL, Goenka S, Boothby M. Sequence motifs in
IL-4R alpha mediating cell-cycle progression of primary lymphocytes. Journal
of Immunology 2005;175:5178–85.
[61] Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK,
et al. PD-L1 regulates the development, maintenance, and function of induced
regulatory T cells. Journal of Experimental Medicine 2009;206:3015–29.
[62] Jones RG, Thompson CB. Revving the engine: signal transduction fuels T cell
activation. Immunity 2007;27:173–8.
[63] Wang R, Dillon CP, Shi LZ, Milasta S, Carter R, Finkelstein D, et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte
activation. Immunity 2012;35:871–82.
[64] Frauwirth KA, Riley JL, Harris MH, Parry RV, Rathmell JC, Plas DR, et al. The CD28
signaling pathway regulates glucose metabolism. Immunity 2002;16:769–77.
[65] Michalek RD, Gerriets VA, Nichols AG, Inoue M, Kazmin D, Chang CY, et al.
Estrogen-related receptor-alpha is a metabolic regulator of effector T-cell activation and differentiation. Proceedings of the National Academy of Sciences of
the United States of America 2011;108:18348–53.
[66] Buller CL, Loberg RD, Fan MH, Zhu Q, Park JL, Vesely E, et al. A GSK-3/TSC2/mTOR
pathway regulates glucose uptake and GLUT1 glucose transporter expression.
American Journal of Physiology: Cell Physiology 2008;295:C836–43.
[67] Gottesdiener KM, Karpinski BA, Lindsten T, Strominger JL, Jones NH, Thompson
CB, et al. Isolation and structural characterization of the human 4F2 heavychain gene, an inducible gene involved in T-lymphocyte activation. Molecular
and Cellular Biology 1988;8:3809–19.
[68] Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy
through direct phosphorylation of Ulk1. Nature Cell Biology 2011;13:132–41.
[69] Pua HH, Guo J, Komatsu M, He YW. Autophagy is essential for mitochondrial
clearance in mature T lymphocytes. Journal of Immunology 2009;182:4046–55.
[70] Jia W, Pua HH, Li QJ, He YW. Autophagy regulates endoplasmic reticulum
homeostasis and calcium mobilization in T lymphocytes. Journal of Immunology 2011;186:1564–74.
[71] Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation.
Nature 2011;469:323–35.
[72] Pua HH, Dzhagalov I, Chuck M, Mizushima N, He YW. A critical role for the
autophagy gene Atg5 in T cell survival and proliferation. Journal of Experimental Medicine 2007;204:25–31.
X. Xu et al. / Seminars in Immunology 24 (2012) 429–435
[73] Li C, Capan E, Zhao Y, Zhao J, Stolz D, Watkins SC, et al. Autophagy is induced in
CD4+ T cells and important for the growth factor-withdrawal cell death. Journal
of Immunology 2006;177:5163–8.
[74] Tamas P, Hawley SA, Clarke RG, Mustard KJ, Green K, Hardie DG, et al. Regulation of the energy sensor AMP-activated protein kinase by antigen receptor
435
and Ca2+ in T lymphocytes. Journal of Experimental Medicine 2006;203:
1665–70.
[75] Paul S, Kashyap AK, Jia W, He YW, Schaefer BC. Selective autophagy of the adaptor protein Bcl10 modulates T cell receptor activation of NF-kappaB. Immunity
2012;36:947–58.